Affiliation:
1. Russian University of People’s Friendship
Abstract
Aim. To evaluate the prognostic value of blood group and IL-28B genotype with respect to dynamics of liver fibrosis (LF) in patients with chronic genotype-1 hepatitis C (HCV-1) who did not respond to antiviral therapy (AVT) with pegylated interferon alpha 2 (peg-IFN-α-2) and ribavarin (RBV) Material and methods. The study included 122 primary patients with HCV-1 who underwent paired liver biopsy or elastometry steam. The main group (n=66) consisted of patients who received AVT (peg-IFN-α-2/RBV) but failed to achieve a sustainable virologic response (SVR). Control group (n=56) comprised patients treated without AVT. Results. Negative dynamics of LF in patients of the main group occurred significantly more frequently than in the placebo group (p=0.025, φ2 criterion). LF dynamic patterns in patients of the main group varied depending on the IL-28B genotype and blood group, p=0.001 and p=0.014 respectively. Factorial analysis of negative LP dynamics in the main group revealed the relationship between blood group (fr=0,931) and IL-28B genotype (fr= 0.960) while classification analysis demonstrated the predictive value of combination of gene IL-28B polymorphism and blood group (p<0.0001). The assessment of probability of negative LF dynamics in the main group (logistic analysis) showed that IL-28B gene genotypes ST/TG, TT/TT,TG,GG and blood group A(II) alone or their combination increase the odds ratio of LF negative dynamics in SVR(-) under conditions of interferon therapy. In patients having blood group 0(I) and combination of gene IL-28B genotypes CC/TT, CT/TT with blood group A(II) the odds ratio of negative dynamics in SVR(-) is reduced under the same conditions. Conclusions. Blood group and IL-28B genotype predict dynamics of liver fibrosis in patients with HCV-1 not responding to interferon therapy.
Publisher
Medical Informational Agency Publishers
Reference21 articles.
1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29(Suppl. 1): 74—81.
2. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C. et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011; 31(Suppl. 2): 30—60.
3. Burnevich E.Z., Nikulkina E.N., Shchanitsina S.E. Ombiasy + paritare-VIR/ritonavir and dazabuli ± ribavirin — optimal antiviral therapy of chronic hepatitis C drugs of direct action. Klinicheskaya farmakologiya i terapiya. 2015; 24(2): 13—20. (in Russian)
4. Burnevich E.Z., Shchanitsina S.E. Antiviral therapy of chronic hepatitis C based on interferon-α: patterns and principles. Klinicheskaya farmakologiya i terapiya. 2016; 25(1): 8—13. (in Russian)
5. Poynard T., Huthcicon J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P. et al. Impact of interferon Alpha -2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology. 2000; 32(5): 1131—7.